The post SUI trades below $1 as institutional access expands via staked ETFs appeared on BitcoinEthereumNews.com. Sui’s native token [SUI] continued to trade belowThe post SUI trades below $1 as institutional access expands via staked ETFs appeared on BitcoinEthereumNews.com. Sui’s native token [SUI] continued to trade below

SUI trades below $1 as institutional access expands via staked ETFs

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Sui’s native token [SUI] continued to trade below the $1 mark on Wednesday, even as institutional access to the asset broadened following the launch of two separate staked SUI exchange-traded products in the U.S.

The muted price reaction came despite announcements from Canary Capital and Grayscale on 18 February. They unveiled investment vehicles designed to offer regulated exposure to SUI while capturing on-chain staking rewards.

At the time of writing, SUI was trading around $0.95, down more than 1.7% on the day. It was trading near its lowest levels since late 2023, according to TradingView data.

Two staked SUI products go live

On Wednesday, 18 February, Canary Capital announced the launch of the Canary Staked SUI ETF [SUIS], which began trading on Nasdaq. 

The fund provides spot exposure to SUI, the native token of the Sui Network, while also participating in the network’s proof-of-stake validation process. Net staking rewards are reflected directly in the fund’s net asset value.

According to Canary, the product is aimed at investors seeking regulated exposure to emerging Layer-1 networks.

On the same day, Grayscale also rolled out its own staked SUI product [GSUI], expanding its suite of single-asset crypto vehicles beyond Bitcoin and Ethereum. 

While structured differently from an ETF, the Grayscale product similarly allows investors to gain exposure to SUI alongside staking yield. It reinforces the firm’s longer-term view on proof-of-stake networks.

The near-simultaneous launches suggest rising institutional interest in Sui as an investable network, even as broader market sentiment remains cautious.

Institutional access widens as price stays under pressure

Despite the expansion in access, SUI’s price failed to respond positively to the news. The token has been locked in a steady downtrend since late 2025, falling from highs above $3 to below $1, with recent rallies repeatedly rejected.

Trading volume spiked briefly following the ETF announcements. Still, momentum quickly faded, indicating that the new products have yet to attract significant speculative inflows.

Source: TradingView

The lack of immediate upside may reflect the current macro backdrop and a broader shift toward long-term accumulation rather than short-term positioning. 

Staked products, in particular, tend to appeal more to allocators focused on yield and network fundamentals than to momentum-driven traders.


Final Summary

  • Canary’s SUIS and Grayscale’s GSUI expand regulated access to SUI with staking yield, signalling growing institutional product interest in the network.
  • SUI still trading below $1 suggests the market is prioritizing broader risk conditions over ETF/ETP launches, keeping near-term price reaction muted.

Next: $16B Fed injection meets BTC/Gold 11-year low – Rare buying signal?

Source: https://ambcrypto.com/sui-trades-below-1-as-institutional-access-expands-via-staked-etfs/

Market Opportunity
SUI Logo
SUI Price(SUI)
$0.9554
$0.9554$0.9554
+5.80%
USD
SUI (SUI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.